| (Values in U.S. Thousands) | Mar, 2025 | Mar, 2024 | Mar, 2023 | Mar, 2022 | Mar, 2021 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -8,480 | -18,880 | -7,600 | -18,010 | -13,100 |
| Net Income Growth | +55.08% | -148.42% | +57.80% | -37.48% | -110.61% |
Medicenna Thera Corp (MDNAF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Medicenna Therapeutics Corp is a clinical stage immuno-oncology company. It is engaged in developing engineered versions of IL-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines ECs for the treatment of cancer. Medicenna Therapeutics Corp is based in Toronto, Canada.
Fiscal Year End Date: 03/31